{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:01:08Z","timestamp":1785765668312,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory tract infection in early infancy, with the highest burden concentrated in the first months of life. Two immunoprophylactic strategies\u2014maternal RSVpreF vaccination and long-acting monoclonal antibodies\u2014now offer effective early life protection, yet differ in biological mechanisms, operational requirements, and programmatic implications. Maternal vaccination induces high-quality neutralizing antibodies that are transferred transplacentally, providing immediate protection from birth and integrating efficiently into antenatal care platforms. However, its effectiveness is constrained by gestational timing, physiological antibody waning, and reduced protection when vaccination occurs shortly before delivery. Long-acting monoclonal antibodies, including nirsevimab and clesrovimab, bypass maternal immune variability and provide standardized, season-long protection across gestational ages, including preterm infants. Economic evaluations demonstrate that both strategies can be cost-effective, though their relative value depends on local epidemiology, pricing, and coverage patterns. Economic outcomes for monoclonal antibodies and maternal vaccination are highly context-dependent and influenced by regional RSV epidemiology, healthcare utilization, product pricing, and implementation capacity, rather than universally favoring one strategy over the other. Global equity considerations remain critical: disparities in antenatal care access, supply chain fragility, and pricing differentials may widen gaps between high- and low-income countries. Remaining evidence gaps\u2014including long-term safety monitoring, durability of protection, viral evolution, and implementation challenges\u2014underscore the need for continued research and careful integration of these tools into national immunization programs.<\/jats:p>","DOI":"10.3390\/vaccines14080673","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:57:56Z","timestamp":1785761876000},"page":"673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory Syncytial Virus Prophylaxis: Maternal Vaccination or Long-Acting Monoclonal Antibodies? A Brief Narrative Review of Current Status"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-3698","authenticated-orcid":false,"given":"Fani","family":"Ladomenou","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Medical School, University of Ioannina, 41510 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna-Andriana","family":"Psarra","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Medical School, University of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-0813","authenticated-orcid":false,"given":"Despoina","family":"Gkentzi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Medical School, University of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2026, June 02). Respiratory Syncytial Virus (RSV). Available online: https:\/\/www.who.int\/health-topics\/respiratory-syncytial-virus."},{"key":"ref_2","unstructured":"European Vaccination Information Portal (2026, June 02). Respiratory Syncytial Virus (RSV). Available online: https:\/\/vaccination-info.europa.eu\/en\/rsv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: A prospective birth cohort study","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cohen, R., Nunes, M.C., Rybak, A., Chillotti, L., Kernaleguen, C., Bugnard, F., Greenwood, W., Fahfouhi, Y., Fi\u00e9vez, S., and Blanc, E. (2025). Epidemiology and economic burden of hospitalizations attributable to respiratory syncytial virus infection among infants in France, 2016\u20132023 (EPIBREATHE study). BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-12039-2"},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (CDC) (2026, June 02). RSV in Infants and Young Children: Clinical Guidance and Immunization Options, Available online: https:\/\/www.cdc.gov\/rsv\/infants-young-children\/index.html."},{"key":"ref_6","unstructured":"U.S. Food and Drug Administration (2026, June 02). ABRYSVO (Respiratory Syncytial Virus Vaccine), Prescribing Information. DailyMed, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=be18292e-b1a2-4815-a0ed-003efaa6bea3."},{"key":"ref_7","unstructured":"Centers for Disease Control and Prevention (CDC) (2026, June 02). RSV Vaccine Guidance for Pregnant Women, Available online: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/pregnant-people.html."},{"key":"ref_8","unstructured":"American College of Obstetricians and Gynecologists (2026, June 02). Maternal Respiratory Syncytial Virus (RSV) Vaccination. Practice Advisory, 2023. Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2023\/09\/maternal-respiratory-syncytial-virus-vaccination."},{"key":"ref_9","unstructured":"European Medicines Agency (2026, June 02). Abrysvo: EPAR\u2014European Public Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo."},{"key":"ref_10","unstructured":"Rausch-Phung, E.A., Awosika, A.O., and Patel, P. (2024). Respiratory Syncytial Virus Prefusion F (RSVPreF3) Vaccine. StatPearls, StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000005817","article-title":"Preterm birth frequency and associated outcomes from the MATISSE maternal trial of the bivalent RSV prefusion F protein vaccine","volume":"145","author":"Madhi","year":"2025","journal-title":"Obs. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Association of prenatal RSV vaccination with perinatal outcomes","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2460735","DOI":"10.1001\/jamanetworkopen.2024.60735","article-title":"Respiratory syncytial virus vaccine and nirsevimab uptake among pregnant people and their neonates","volume":"8","author":"Blauvelt","year":"2025","journal-title":"JAMA Netw. Open."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): A multicentre, retrospective, test-negative, case\u2013control study","volume":"25","author":"Vizzotti","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","first-page":"101296","article-title":"Impact and effectiveness of RSV maternal immunization on infant hospitalizations in Buenos Aires: A hospital-based, multicentre, retrospective surveillance cohort study","volume":"52","author":"Razzini","year":"2025","journal-title":"Lancet Reg. Health Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/INF.0000000000004878","article-title":"Maternal immunization with RSVpreF vaccine: Effectiveness in preventing respiratory syncytial virus\u2013associated hospitalizations in infants under 6 months in Argentina: Multicenter case\u2013control study","volume":"44","author":"Gentile","year":"2025","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2616773","DOI":"10.1001\/jamanetworkopen.2026.16773","article-title":"Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants","volume":"9","author":"Rick","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1473-3099(25)00624-3","article-title":"Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: A national, population-based case\u2013control study and cohort analysis","volume":"26","author":"McLachlan","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","unstructured":"UK Health Security Agency (2026). Effectiveness of maternal RSV vaccine in England confirmed. Health Prot. Rep., 20, 1\u20135."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nikolaou, A.I., Soldatou, A., Grantzi, G.-C., Giapros, V., and Ladomenou, F. (2026). Determinants of Maternal RSV Vaccination Uptake: A Narrative Review. Vaccines, 14.","DOI":"10.3390\/vaccines14040293"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"126050","DOI":"10.1016\/j.vaccine.2024.06.018","article-title":"Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?","volume":"42","author":"Holzapfel","year":"2024","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mendes, D., Kang, M., and Law, A. (2026). What Form of RSV Protection Do Women Prefer: Maternal Vaccination or Infant Immunisation? A Cross-Sectional Survey in Europe. Vaccines, 14.","DOI":"10.3390\/vaccines14030238"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"200153","DOI":"10.1016\/j.jpedcp.2025.200153","article-title":"Factors Influencing Parental Decisions on Respiratory Syncytial Virus Immunoprophylaxis","volume":"17","author":"Shedlock","year":"2025","journal-title":"J. Pediatr. Clin. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jama.2025.24082","article-title":"Nirsevimab vs. RSVpreF vaccine for RSV-related hospitalization in newborns","volume":"335","author":"Jabagi","year":"2026","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2352-4642(26)00075-1","article-title":"Effectiveness of nirsevimab immunisation after birth versus RSVpreF maternal vaccination in preventing RSV-related hospitalisations in infants: A population-based retrospective cohort study","volume":"10","author":"Valtuille","year":"2026","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","article-title":"180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): A randomised, controlled, phase 3b trial","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): A population-based prospective observational study","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2400033","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","article-title":"Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg","volume":"29","author":"Ernst","year":"2024","journal-title":"Eurosurveillance"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.15585\/mmwr.mm7345a1","article-title":"Nirsevimab effectiveness against medically attended respiratory syncytial virus illness and hospitalization among Alaska Native children\u2014Yukon-Kuskokwim Delta Region, Alaska, October 2023\u2013June 2024","volume":"73","author":"Lefferts","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: A systematic review and meta-analysis","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): A retrospective observational study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMc2506107","article-title":"Clesrovimab in infants and children at increased risk for severe RSV disease","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41467-026-72659-3","article-title":"Maternal RSV Vaccination Generates High-Affinity Antibodies That Efficiently Transfer to Infants, Providing Enhanced Passive Immunity","volume":"17","author":"Liu","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s41043-026-01270-5","article-title":"Maternal RSV Immunization: Clinical Efficacy, Immunological Mechanisms and Public Health Implications for Preventing Infant Lower Respiratory Tract Infection","volume":"45","author":"Amin","year":"2026","journal-title":"J. Health Popul. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jac\/dkad076","article-title":"Nirsevimab: Review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants","volume":"78","author":"Jorgensen","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","unstructured":"Centers for Disease Control and Prevention (2026, June 17). RSV Vaccines: ACIP Recommendations for Healthcare Providers, Available online: https:\/\/www.cdc.gov\/acip-recs\/hcp\/vaccine-specific\/rsv.html."},{"key":"ref_41","unstructured":"World Health Organization (2024). WHO Global Market Study on RSV Immunization Products, World Health Organization."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"127191","DOI":"10.1016\/j.vaccine.2025.127191","article-title":"Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States","volume":"58","author":"Averin","year":"2025","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2024066461","DOI":"10.1542\/peds.2024-066461","article-title":"Cost-effectiveness of nirsevimab for respiratory syncytial virus in infants and young children","volume":"154","author":"Hutton","year":"2024","journal-title":"Pediatrics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40121-024-01000-6","article-title":"Cost-effectiveness analysis of maternal respiratory syncytial virus vaccine in protecting infants from RSV infection in Japan","volume":"13","author":"Ishiwada","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"127936","DOI":"10.1016\/j.vaccine.2025.127936","article-title":"Cost-effectiveness of infant and maternal RSV immunization strategies in British Columbia, Canada","volume":"68","author":"Taleshi","year":"2025","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101141","DOI":"10.1016\/j.eclinm.2021.101141","article-title":"Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada","volume":"41","author":"Nourbakhsh","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_47","first-page":"100629","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of RSV disease among infants in Canada: A simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_48","unstructured":"International Vaccine Access Center (IVAC) (2026, July 29). VIEW-Hub: RSV Vaccine and Monoclonal Antibody Introduction Status. Johns Hopkins Bloomberg School of Public Health. Available online: https:\/\/view-hub.org\/vaccine\/rsv."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:17:38Z","timestamp":1785763058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vaccines14080673"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14080673","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}